In the enzyme-linked immunosorbent spot (ELISPOT) experiment, small amounts of IFNγ spots in non-OVA peptide-treated lymphocytes may be attributed to nonspecific activation of CTLs in the periphery that ultimately circulate to the tumor and thus tumor-draining lymph nodes. The gene discussed is IFNG; the disease is neoplasm.